Literature DB >> 26278366

Waist circumference, waist-hip ratio, body mass index, and prostate cancer risk: results from the North-American case-control study Prostate Cancer & Environment Study.

Katharina Boehm1, Maxine Sun2, Alessandro Larcher3, Audrey Blanc-Lapierre4, Jonas Schiffmann5, Markus Graefen5, José Sosa5, Fred Saad6, Marie-Élise Parent7, Pierre I Karakiewicz8.   

Abstract

INTRODUCTION: The evidence on the association between anthropometric measures quantifying body fatness and prostate cancer (PCa) risk is not entirely consistent. Associations among waist circumference (WC), waist-hip ratio, body mass index (BMI), and PCa risk were assessed in a population-based case-control study. PATIENTS AND METHODS: The study included 1933 incident PCa cases diagnosed between 2005 and 2009. Population controls were 1994 age-matched (±5y) Montreal residents selected from electoral lists. Information on sociodemographics, medical history including PCa screening, height, weight, and waist and hip circumferences was collected through interviews. Logistic regression was used to assess odds ratios (ORs) for the association between anthropometric measures, and overall and grade-specific PCa.
RESULTS: After adjustment for BMI, an excess risk of high-grade PCa (Gleason≥7) was associated with a WC ≥102cm (OR = 1.47 [1.22-1.78]) and with a waist-hip ratio >1.0 (OR = 1.20 [1.01-1.43]). Men with a BMI≥30kg/m(2) had a lower risk of PCa, regardless of grade. Restricting to subjects recently screened for PCa did not alter findings.
CONCLUSION: Elevated BMI was associated with a lower risk of PCa, regardless of grade. Contrastingly, abdominal obesity, when adjusted for BMI, yielded results in the opposite direction. Taken together, our observations suggest that the specific body fat distribution (abdominal), for a given BMI, is a predictor of PCa risk, whereas BMI alone is not. BMI and abdominal obesity, especially when measured by the WC, should be examined conjointly in future studies on this issue and may require consideration at patient counseling.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Abdominal fat; Body mass index; Case-control study; Obesity; Prostate cancer; Waist circumference; Waist-hip ratio

Mesh:

Year:  2015        PMID: 26278366     DOI: 10.1016/j.urolonc.2015.07.006

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  17 in total

1.  Is Body Mass Index the Best Adiposity Measure for Prostate Cancer Risk? Results From a Veterans Affairs Biopsy Cohort.

Authors:  Lourdes Guerrios-Rivera; Lauren Howard; Jennifer Frank; Amanda De Hoedt; Devon Beverly; Delores J Grant; Cathrine Hoyo; Stephen J Freedland
Journal:  Urology       Date:  2017-04-10       Impact factor: 2.649

2.  Larger men have larger prostates: Detection bias in epidemiologic studies of obesity and prostate cancer risk.

Authors:  Andrew Rundle; Yun Wang; Sudha Sadasivan; Dhananjay A Chitale; Nilesh S Gupta; Deliang Tang; Benjamin A Rybicki
Journal:  Prostate       Date:  2017-03-27       Impact factor: 4.104

3.  Association of Anthropometric Measures with Prostate Cancer among African American Men in the NCI-Maryland Prostate Cancer Case-Control Study.

Authors:  Margaret S Pichardo; Cheryl J Smith; Tiffany H Dorsey; Christopher A Loffredo; Stefan Ambs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-21       Impact factor: 4.254

Review 4.  Contribution of Adipose Tissue to Development of Cancer.

Authors:  Alyssa J Cozzo; Ashley M Fuller; Liza Makowski
Journal:  Compr Physiol       Date:  2017-12-12       Impact factor: 9.090

5.  Overall and central obesity and prostate cancer risk in African men.

Authors:  Akindele Olupelumi Adebiyi; Ann W Hsing; Ilir Agalliu; Wei-Kaung Jerry Lin; Janice S Zhang; Judith S Jacobson; Thomas E Rohan; Ben Adusei; Nana Yaa F Snyper; Caroline Andrews; Elkhansa Sidahmed; James E Mensah; Richard Biritwum; Andrew A Adjei; Victoria Okyne; Joana Ainuson-Quampah; Pedro Fernandez; Hayley Irusen; Emeka Odiaka; Oluyemisi Folake Folasire; Makinde Gabriel Ifeoluwa; Oseremen I Aisuodionoe-Shadrach; Maxwell Madueke Nwegbu; Audrey Pentz; Wenlong Carl Chen; Maureen Joffe; Alfred I Neugut; Thierno Amadou Diallo; Mohamed Jalloh; Timothy R Rebbeck
Journal:  Cancer Causes Control       Date:  2021-11-16       Impact factor: 2.506

6.  Association of Anthropometric Measures With the Risk of Prostate Cancer in the Multiethnic Cohort.

Authors:  Olivia Sattayapiwat; Peggy Wan; Brenda Y Hernandez; Loic Le Marchand; Lynne Wilkens; Christopher A Haiman
Journal:  Am J Epidemiol       Date:  2021-09-01       Impact factor: 5.363

7.  Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer.

Authors:  Nagi B Kumar; Roshni Patel; Julio Pow-Sang; Philippe E Spiess; Raoul Salup; Christopher R Williams; Michael J Schell
Journal:  Oncotarget       Date:  2017-06-29

8.  Waist-hip Ratio (WHR), a Better Predictor for Prostate Cancer than Body Mass Index (BMI): Results from a Chinese Hospital-based Biopsy Cohort.

Authors:  Bo Tang; Cheng-Tao Han; Gui-Ming Zhang; Cui-Zhu Zhang; Wei-Yi Yang; Ying Shen; Adriana C Vidal; Stephen J Freedland; Yao Zhu; Ding-Wei Ye
Journal:  Sci Rep       Date:  2017-03-08       Impact factor: 4.379

9.  Relationship of self-reported body size and shape with risk for prostate cancer: A UK case-control study.

Authors:  Mohammad Aladwani; Artitaya Lophatananon; Fredie Robinson; Aneela Rahman; William Ollier; Zsofia Kote-Jarai; David Dearnaley; Govindasami Koveela; Nafisa Hussain; Reshma Rageevakumar; Diana Keating; Andrea Osborne; Tokhir Dadaev; Mark Brook; Rosalind Eeles; Kenneth R Muir
Journal:  PLoS One       Date:  2020-09-17       Impact factor: 3.240

10.  Clinical and biochemical markers of visceral adipose tissue activity: Body mass index, visceral adiposity index, leptin, adiponectin, and matrix metalloproteinase-3. Correlation with Gleason patterns 4 and 5 at prostate biopsy.

Authors:  Vincenzo Serretta; Alberto Abrate; Simone Siracusano; Cristina Scalici Gesolfo; Marco Vella; Fabrizio Di Maida; Antonina Cangemi; Giuseppe Cicero; Elisabetta Barresi; Chiara Sanfilippo
Journal:  Urol Ann       Date:  2018 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.